Cencora ve 3. čtvrtletí zvýšila tržby v U.S. Healthcare Solutions o 5 % na 74,9 miliardy USD a provozní zisk segmentu vzrostl o 16 % na 966 milionů USD. Tahounem byl specializovaný byznys a OneOncology.
Key Takeaways COR's U.S. Healthcare Solutions revenues rose 5%, with specialty strength driving 16% operating income growth.OneOncology is driving growth through integration, new services, trials and tuck-in acquisitions.GLP-1 growth boosts volumes, while drug-price cuts and the MWI divestiture weigh on earnings prospects. Cencora (COR - Free Report) is well poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #3 (Hold) company’s shares have lost 0.2% in the year-to-date period compared with the industry’s 3.1% decline. However, the S&P 500 Index has gained 11.4% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $64.19 billion.
COR’s bottom line is anticipated to improve 9.9% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 0.76%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive Factors Driving COR’s ProspectsU.S. Healthcare Solutions Shows Momentum: Cencora’s U.S. Healthcare Solutions business is showing accelerating underlying momentum, particularly in specialty. Fiscal third-quarter revenues rose 5% to $74.9 billion, while segment operating income increased 16% to $966 million. Specialty strength across health systems, physician practices and MSOs drove the improvement, with OneOncology and RCA outperforming expectations.
Excluding the lost oncology customer and OneOncology’s contribution, core operating income still grew at a double-digit rate, versus 7% in the prior quarter. The company also expects fourth-quarter results to deliver strong double-digit growth as it fully laps the oncology customer loss and benefits from an easier expense comparison. This suggests that underlying demand and execution are strengthening beyond acquisition-related contributions.
OneOncology Offers Significant Runway for Growth: OneOncology is emerging as a meaningful long-term growth platform beyond its initial distribution and GPO benefits. Management said the acquisition is performing modestly above expectations, while its three-phase value-creation plan is progressing through integration, capability sharing and new services. The most attractive opportunity is clinical trials.
OneOncology remains in the early stages of building this business, unlike RCA’s more mature platform. Cencora expects community-based oncology sites to expand trial access and improve patient accrual, creating value for both physicians and pharmaceutical manufacturers. Continued physician additions and tuck-in acquisitions could increase network density, strengthen manufacturer relationships and create higher-value services, potentially making the MSO platform an increasingly important earnings contributor.
Specialty Logistics and International Operations Provide Diversification: Cencora’s specialty logistics and international operations are providing an increasingly diversified earnings stream. International Healthcare Solutions revenues increased 6% to $7.7 billion, while operating income rose 21% as World Courier and European 3PL delivered double-digit operating-income growth.
World Courier is benefiting from stabilization after a challenging fiscal 2025, while 3PL gained from strong renewals and new business wins. These businesses also benefit from specialized capabilities and Cencora’s pharmaceutical-centric positioning that differentiate it from broader logistics competitors.
Although a one-time European pricing-timing benefit will not repeat in the fourth quarter, the underlying specialty logistics pipeline remains healthy, improving the segment’s ability to offset volatility in U.S. pharmaceutical distribution.
GLP-1 Growth and Part B Biosimilars Create Structural Volume Opportunities: GLP-1 demand is becoming an important structural volume driver for Cencora. U.S. Healthcare Solutions recorded a $2.3 billion year-over-year increase in GLP-1 sales, with management indicating approximately 25% growth, broadly in line with expectations.
While GLP-1 products can carry different economics from traditional pharmaceuticals, the rapid expansion increases distribution volumes and reinforces Cencora’s relevance to manufacturers and downstream customers.
The company’s specialty-centric model should benefit from continued pharmaceutical innovation, including biosimilars and complex therapies. Cencora also sees Part B biosimilars as particularly attractive because its distribution, GPO and MSO services provide greater value around physician-administered products, creating a more favorable profit opportunity than Part D switches.
Key Challenges for COR StockDrug-price Reductions Continue to Suppress Headline Growth: Manufacturer list-price reductions remain a major drag on Cencora’s headline revenue growth and could continue to obscure underlying operating momentum. In the fiscal third quarter, U.S. Healthcare Solutions revenues were supported by $2.3 billion of incremental GLP-1 sales, but this was more than offset by a $2.4 billion headwind from manufacturer list-price reductions.
The company also absorbed the prior-year loss of an oncology customer and lower sales to a large mail-order customer. Management expects full-year U.S. revenue growth in the lower half of its 4-6% guided range. This highlights the structural challenge of generating revenue growth in a distribution model where lower drug prices can reduce reported sales even when volumes and underlying profitability remain healthy.
MWI Divestiture Could Create Meaningful Earnings Headwind: Cencora’s near-term earnings outlook faces a difficult comparison from the pending MWI Animal Health transaction with Covetrus. Management expects the deal to create an approximately $150 million operating-income headwind within Other if it closes around the midpoint of fiscal 2027, translating into an estimated 35-cent EPS headwind after accounting for the transaction structure. The company has not yet provided a firm closing timetable, as regulatory review remains ongoing.
Although the transaction includes upfront cash, preferred equity and common equity that partially offset the earnings impact, the divestiture would reduce MWI’s reported earnings contribution. Investors therefore face a potential earnings reset in fiscal 2027, even if the core healthcare businesses continue to perform strongly.
Regulatory and Pricing Uncertainty Could Pressure Specialty Economics: Regulatory and pricing uncertainty remains a persistent risk to Cencora’s specialty and distribution economics. Management is assessing proposed changes to 340B and ASP rules, acknowledging that the eventual impact could vary across its broad customer base and is not yet quantifiable.
Cencora believes policymakers are unlikely to reduce physician reimbursement, but the outcome remains dependent on future regulatory decisions. The company expects international revenue growth to slow to approximately 8% as the stronger U.S. dollar weighs on reported results, while a favorable manufacturer price-adjustment timing benefit in European distribution is not expected to repeat in the fourth quarter. These factors increase the risk that favorable current trends normalize faster than underlying volume growth suggests.
Estimate TrendCOR has been witnessing a stable improving revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 8 cents to $17.79 per share.
The consensus mark for fourth-quarter fiscal 2026 revenues is pegged at $88.09 billion, indicating a 5.2% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.51, implying year-over-year growth of 17.5%.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
Cencora spustila CGT Enablement, aby zdravotnickým systémům pomohla budovat a škálovat programy buněčné a genové terapie. Služba cílí na finanční, provozní i lékárenské překážky.
Key Takeaways Cencora launched CGT Enablement to help health systems build and scale cell and gene therapy programs.COR targets financial, operational and pharmacy challenges tied to integrating complex CGT treatments.Cencora has completed 170 CGT consulting projects and supported 35 FDA-approved cell and gene therapies. Cencora (COR - Free Report) recently launched Cell and Gene Therapy (CGT) Enablement through its Accelerate Pharmacy Solutions business, offering support to health systems to evaluate, build and scale CGT programs. The new service is designed to improve operational readiness, financial confidence and program scalability while helping reduce barriers to care and expand patient access to advanced therapies.
Per management, cell and gene therapies have the potential to transform care for patients with serious and complex diseases, but delivering these therapies requires close coordination across strategy, finance, clinical operations, pharmacy and patient access. The company is building on its existing capabilities to provide health systems with tailored support, including market landscape and readiness assessments, governance design, implementation and optimization, to help them launch or expand their CGT programs.
Likely Trend of COR Stock Following the NewsShares of COR have inched up 0.3% since the announcement on Wednesday. Year to date, shares of the company have lost 0.2% against the industry’s 3.9% growth. The S&P 500 increased 12.5% in the same time frame.
The launch is likely to support Cencora’s long-term growth prospects by expanding its CGT capabilities and strengthening its relationships with health systems. As the number of approved therapies and clinical trials increases, health systems may require greater financial, operational and pharmacy support to integrate these complex treatments. Cencora’s new offering positions the company to capture the growing demand while complementing its existing CGT commercialization, specialty distribution and provider solutions.
COR currently has a market capitalization of $64.19 billion.
Image Source: Zacks Investment Research
More on the NewsCencora’s new CGT Enablement service comes as health systems face growing challenges in preparing for the increasing adoption of cell and gene therapies. More than 35 CGTs have been approved by the FDA so far, while more than 1,700 clinical trials are underway globally. However, only 4% of health system pharmacy leaders surveyed in a recent report said their organizations were fully prepared to integrate these therapies, highlighting significant gaps in infrastructure, resource allocation and operational alignment.
Cencora’s CGT Enablement team will support health systems across three areas. Financial confidence services will provide insights into the CGT market, therapy-specific financial considerations, reimbursement dynamics and site-of-care factors. Operational readiness support will include readiness assessments, gap analysis, strategic roadmaps, governance design and workflow planning. Scalable growth services will help establish repeatable operating models that support coordinated execution across pharmacy, finance, clinical operations, strategy and patient access teams.
The offering builds on Cencora’s broader CGT expertise across the product lifecycle, including commercialization support, specialty distribution and provider solutions. Cencora has completed 170 upstream CGT consulting projects, delivered more than 29,000 CGT shipments annually and supported 35 FDA-approved CGTs. By combining these capabilities with Accelerate Pharmacy Solutions’ pharmacy and supply chain expertise, the company aims to help health systems expand CGT programs across therapies, sites and indications.
Industry Prospects Favoring the MarketGoing by the data provided by Fortune Business Insights, the global cell and gene therapy market is valued at $16.45 billion in 2026 and is expected to witness a CAGR of 31.1% through 2034.
Factors like the increasing prevalence of rare diseases and cancers, growing number of approved therapies, expanding clinical trial pipelines, rising demand for advanced treatments and increasing focus on operational readiness and patient access are supporting the market’s growth.
Other NewsCencora recently delivered mixed fiscal third-quarter 2026 results, with earnings beating estimates while revenues fell short. Performance was supported by specialty pharmaceutical volumes, GLP-1 demand and growth in international healthcare solutions. OneOncology boosted U.S. Healthcare Solutions, while Profarma and MWI Animal Health added to growth. The company raised its fiscal 2026 adjusted earnings outlook. However, lower-margin GLP-1 sales, higher OneOncology expenses and increased interest costs remain profitability headwinds.
In June, Cencora launched the next-generation Nucleus inventory management solution and initiated a multi-site pilot across more than 20 specialty physician practice locations. The enhanced platform is designed to help providers manage increasingly complex medication workflows with greater efficiency, visibility and control.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Cencora zvýšila výhled upraveného EPS pro fiskální rok 2026 na 17,75–17,95 USD po silnějším růstu upraveného zisku ve 3. čtvrtletí. Upravený zisk na akcii vzrostl meziročně o 12 % na 4,48 USD.
Key Takeaways Cencora lifted fiscal 2026 adjusted EPS guidance to $17.75-$17.95 after stronger third-quarter profits.COR's U.S. segment profit rose 15.9%, helped by OneOncology, specialty sales and higher pharma volumes.Cencora's international operating income rose 20.8%, driven by European distribution and specialty logistics. Cencora (COR - Free Report) raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks Consensus Estimate by 2.5%.
The investor question is whether specialty-driven operating leverage can keep outweighing lower-margin product mix and higher financing costs. Recent results suggest specialty is doing more of the earnings work, even as reported revenue growth remains pressured by pricing changes and customer losses.
Cencora’s Q3 Beat Leads to a Higher EPS OutlookThird-quarter revenues increased 5.1% to $84.76 billion, while adjusted operating income advanced 17% to $1.24 billion. Adjusted operating margin improved 15 basis points to 1.46% as gross profit growth outpaced the increase in operating expenses.
Cencora lifted fiscal 2026 adjusted earnings guidance to $17.75-$17.95 per share from $17.70-$17.90. It also narrowed adjusted operating income growth expectations upward to 13%-14% from 12%-14%, while maintaining consolidated revenue growth guidance of 4%-6%.
Image Source: Zacks Investment Research
COR’s U.S. Healthcare Business Drives Profit GrowthU.S. Healthcare Solutions revenues rose 4.9% to $74.9 billion, supported by higher unit volumes, specialty product sales and GLP-1 demand. Segment operating income climbed 15.9% to $966.2 million, aided by OneOncology and increased pharmaceutical sales.
Management said OneOncology and Retina Consultants of America performed ahead of expectations, while the core business generated double-digit organic operating income growth excluding OneOncology and the lost oncology customer. McKesson Corporation (MCK - Free Report) is also expanding its oncology and multispecialty platform, including an agreement announced in August to acquire Precision Medicine Group for about $2.25 billion. Cardinal Health (CAH - Free Report) , another major pharmaceutical distributor, provides a useful industry comparison because pharmaceutical distribution remains central to its business.
Cencora’s International Segment Adds MomentumInternational Healthcare Solutions revenues increased 5.9% to $7.7 billion, or 6.1% at constant currency. Operating income rose 20.8% to $165.9 million and advanced 23.1% at constant currency.
European distribution and global specialty logistics drove the improvement. The quarter also benefited from the timing of manufacturer price changes in a developing market, a factor management does not expect to repeat in the fourth quarter.
COR’s GLP-1 Mix and Interest Costs Temper the UpsideGLP-1 sales increased $2.3 billion year over year and supported U.S. revenue growth, but these products carry lower gross profit margins than many other categories. Cencora also absorbed a $2.4 billion revenue headwind from manufacturer list-price reductions, along with the effects of a lost oncology customer and lower sales to a large mail-order customer.
Financing is another offset. Net interest expense increased 72% to $140.7 million, primarily because of debt raised to help fund the OneOncology acquisition and lower interest income. Cencora has made progress on debt repayment, but higher borrowing costs remain part of the earnings equation.
Cencora’s Strong Style Scores Meet a Hold SignalThe raised outlook and specialty execution support the earnings picture, but mix, pricing and financing pressures keep the near-term setup balanced. Cencora currently carries a Zacks Rank #3 (Hold), which points to a neutral near-term earnings-estimate signal rather than a clear buy or sell indication. McKesson and Cardinal Health currently carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy)stocks here.
COR has a Growth Score of A, VGM Score of A and Value Score of B, indicating favorable characteristics across growth and broader style measures. Its Momentum Score of D is less supportive. Because Style Scores are designed to complement the Zacks Rank, the combination suggests attractive fundamental traits alongside a more measured near-term view.
Connor Clark & Lunn Investment Management ve 2. čtvrtletí získala nový podíl v Cencora za zhruba 841 000 USD. Cencora zároveň oznámila zpětný odkup akcií za 2 mld. USD.
Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,973 shares of the company’s stock, valued at approximately $841,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. bought a new position in Cencora in the second quarter worth about $4,866,000. Te Ahumairangi Investment Management Ltd bought a new position in shares of Cencora during the second quarter valued at approximately $2,142,000. Mission Financial Group LLC bought a new position in shares of Cencora during the second quarter valued at approximately $396,000. Globeflex Capital L P acquired a new stake in shares of Cencora during the 2nd quarter worth approximately $974,000. Finally, Haverford Trust Co bought a new stake in shares of Cencora in the 2nd quarter worth approximately $241,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Insider Transactions at Cencora In other news, EVP Elizabeth S. Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.38% of the stock is currently owned by insiders.
Cencora Trading Up 0.0% NYSE:COR opened at $322.12 on Monday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $61.47 billion, a price-to-earnings ratio of 23.93, a PEG ratio of 1.85 and a beta of 0.57. The business has a fifty day moving average of $307.38 and a 200-day moving average of $310.51. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The business had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $4.00 earnings per share. Equities analysts predict that Cencora, Inc. will post 17.87 earnings per share for the current year.
Cencora declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.
Cencora Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, August 14th. Cencora’s payout ratio is 17.83%.
Analyst Ratings Changes A number of research analysts recently issued reports on COR shares. Royal Bank Of Canada assumed coverage on Cencora in a research report on Wednesday, August 19th. They set a “sector perform” rating and a $330.00 price objective for the company. Robert W. Baird set a $370.00 target price on Cencora in a research note on Thursday, August 6th. UBS Group raised their target price on Cencora from $412.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $370.85.
Get Our Latest Report on COR
Cencora Company Profile (Free Report)
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Stories Five stocks we like better than Cencora Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
Advisors Capital Management ve 2. čtvrtletí získala nový podíl v Cencora, když koupila 2 644 akcií za zhruba 748 000 USD. Cencora zároveň oznámila EPS 4,48 USD a tržby 84,75 miliardy USD, obojí nad odhady.
Advisors Capital Management LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,644 shares of the company’s stock, valued at approximately $748,000.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after buying an additional 221,570 shares in the last quarter. BlackRock Inc. acquired a new stake in Cencora in the second quarter valued at approximately $5,154,136,000. State Street Corp raised its holdings in shares of Cencora by 1.3% in the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after acquiring an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after buying an additional 4,123,795 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.
Cencora Price Performance Cencora stock opened at $317.89 on Friday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $60.66 billion, a price-to-earnings ratio of 23.62, a price-to-earnings-growth ratio of 1.81 and a beta of 0.57. The firm has a 50-day moving average of $302.59 and a two-hundred day moving average of $311.89. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.
Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%.Cencora’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $4.00 EPS. On average, research analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current year. Cencora declared that its board has authorized a share repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
Cencora Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 17.83%.
Insider Transactions at Cencora In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.38% of the company’s stock.
Wall Street Analysts Forecast Growth COR has been the subject of a number of analyst reports. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 6th. Barclays dropped their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Royal Bank Of Canada started coverage on shares of Cencora in a research note on Wednesday. They issued a “sector perform” rating and a $330.00 price target for the company. Wells Fargo & Company raised their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.85.
View Our Latest Analysis on Cencora
Cencora Profile (Free Report)
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles Five stocks we like better than Cencora Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
Cencora ve 3. čtvrtletí zvýšila upravený provozní zisk o 17 % a upravený zisk na akcii o 12 %; zároveň zvedla celoroční výhled upraveného EPS na 17,75 až 17,95 USD.
McKesson's Compounding Keeps Adding UpCencora NYSE: COR reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Adjusted operating income rose 17% from the prior-year quarter, while adjusted earnings per share increased 12%, supported in part by the company’s share repurchases. Revenue increased 5% to $84.8 billion, and adjusted gross profit climbed 23% to $3.5 billion.
Get Cencora alerts:
Active ETFs Surge Past Passive, and These Are in the Lead“Our third quarter performance reflects the strength of our pharmaceutical-centric strategy, the breadth of our specialty platform, and our disciplined capital deployment,” Chief Financial Officer Eva Boratto said on her first earnings call after joining the company in June.
Cencora raised its fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95, from a previous range of $17.70 to $17.90. The company maintained its adjusted free cash flow outlook of approximately $3 billion for the full year.
U.S. Segment Results Driven by Specialty Top 3 S&P 500 Winners in a Losing MarketU.S. Healthcare Solutions revenue rose 5% to $74.9 billion. The company cited specialty growth across health systems and physician practices, along with a $2.3 billion year-over-year increase in GLP-1 sales.
Those gains were partly offset by $2.4 billion of revenue pressure from manufacturer list-price reductions, the 2025 loss of an oncology customer and lower sales to a large mail-order customer.
U.S. Healthcare Solutions operating income increased 16% to $966 million. Boratto said specialty growth extended across Cencora’s management services organizations, health systems and community-provider businesses. Both the OneOncology and Retina Consultants of America, or RCA, MSO platforms performed ahead of expectations, she said.
Excluding OneOncology’s contribution and the prior loss of the oncology customer, the company’s core business generated double-digit organic operating income growth, management said.
CEO Bob Mauch said the company saw a sequential rebound in specialty utilization from the fiscal second quarter. Oncology was the larger contributor, while retina also supported the improvement, according to Boratto.
Mauch highlighted the importance of biosimilars, particularly in Medicare Part B’s physician-administered, buy-and-bill market. While biosimilars remain incrementally positive in Part D, he said their profit opportunity is greater in Part B because Cencora provides broader distribution, group purchasing, manufacturer and physician-support services.
“Part B will always be good, and we feel very confident about the durability of that over the long term,” Mauch said.
OneOncology Integration and MSO Strategy Cencora acquired OneOncology in February 2026 and said the business is performing modestly ahead of its initial operating-income expectations. The acquisition contributed to higher gross profit, operating expenses and interest expense during the quarter.
The company said it expects OneOncology to remain neutral to adjusted EPS on a 12-month basis, net of financing. Boratto also noted that Cencora changed its treatment of a non-controlling loss related to OneOncology’s UUG subsidiary during the third quarter, though the accounting change had no impact on operating income.
Mauch described Cencora’s MSO value-creation strategy in three phases:
Integrating the MSOs into Cencora and providing the company’s existing capabilities; Sharing capabilities across the platform, including clinical-trial services; Developing new services and analytics solutions for physicians and pharmaceutical manufacturers. He said RCA is further along in developing its clinical-trials platform, while OneOncology remains in earlier stages and offers substantial room for growth. Cencora plans to focus MSO investment on tuck-in acquisitions within oncology and retina, which Mauch said are currently the two specialties the company views as pharmaceutical-centric.
International Growth and Capital Deployment International Healthcare Solutions revenue rose 6% to $7.7 billion, both as reported and on a constant-currency basis. Operating income increased 21% as reported, or 23% in constant currency, to $166 million.
The international performance reflected growth in European distribution, World Courier and European third-party logistics operations. Cencora said its European distribution business continued to benefit from the timing of manufacturer price adjustments in a developing-market country, though it does not expect that benefit in the fourth quarter.
World Courier showed momentum after a challenging fiscal 2025 market, while the European 3PL business benefited from renewals, pricing initiatives and new business wins, Boratto said.
The company ended June with $2.8 billion in cash and year-to-date adjusted free cash flow of $1.1 billion. It also repaid the full $800 million balance of its RCA financing term loan, including $400 million during the June quarter and another $400 million in July.
Cencora repurchased $1 billion of shares during the quarter at an average price of $268 per share, reducing diluted share count by 0.7% year over year to 193.9 million shares. The repurchases increased expected net interest expense for the year to about $490 million because of lower interest income, the company said.
Updated Outlook and Fiscal 2027 Considerations For fiscal 2026, Cencora now expects consolidated adjusted operating income growth of 13% to 14%. It projects U.S. Healthcare Solutions operating income growth of 14.5% to 15.5%, International Healthcare Solutions operating income growth of approximately 9%, and Other operating income growth of approximately 10%.
The company expects U.S. Healthcare Solutions revenue growth to fall in the lower half of its previously issued 4% to 6% range. It now forecasts International Healthcare Solutions revenue growth of approximately 8% as reported and approximately 7% on a constant-currency basis, citing a stronger dollar during the second half of the year.
For fiscal 2027, management said it will provide formal guidance on its November earnings call. Cencora noted that if its planned merger of MWI Animal Health with Covetrus closes at the midpoint of fiscal 2027, it would create an estimated $150 million operating-income headwind in the Other segment and an approximate $0.35 EPS headwind after considering the transaction structure.
The company said it has no update on the timing of the proposed EyeSouth retina carve-out acquisition and advised against including it in fiscal 2027 estimates at this point.
Mauch said Cencora remains confident in its long-term growth framework, supported by its U.S. and international businesses, specialty capabilities and broad customer portfolio.
About Cencora (NYSE:COR)Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Cencora Right Now?Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Cencora (COR - Free Report) came out with quarterly earnings of $4.48 per share, beating the Zacks Consensus Estimate of $4.37 per share. This compares to earnings of $4 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +2.52%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $4.8 per share when it actually produced earnings of $4.75, delivering a surprise of -1.04%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Cencora, which belongs to the Zacks Medical Services industry, posted revenues of $84.75 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.16%. This compares to year-ago revenues of $80.66 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cencora shares have lost about 9.3% since the beginning of the year versus the S&P 500's gain of 13%.
What's Next for Cencora?While Cencora has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cencora was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.54 on $88.7 billion in revenues for the coming quarter and $17.79 on $337.93 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Sotera Health Company (SHC - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.
This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Sotera Health Company's revenues are expected to be $311.13 million, up 5.7% from the year-ago quarter.
Cencora má za fiskální 3Q vykázat tržby 84,89 miliardy USD, tedy o 5,2 % více, a EPS 4,37 USD, což je meziročně o 9,3 % výše. Zisk podpoří speciality pharmaceuticals a onkologické služby.
Key Takeaways Cencora is expected to post 5.2% revenue growth and 9.3% higher EPS in fiscal Q3.COR's specialty pharmaceuticals and oncology services are expected to support operating income.COR may see margin expansion despite pricing changes, biosimilar conversions and higher interest expense. Cencora (COR - Free Report) is slated to report third-quarter fiscal 2026 results on Aug. 5, before market open.
In the last reported quarter, the company delivered a negative earnings surprise of 1.04%. COR’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.59%.
Cencora’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $84.89 billion, up 5.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $4.37 per share, indicating an improvement of 9.3% from the prior-year quarter’s figure.
So far this year, COR’s shares have lost 7.8% compared with the industry’s decline of 1.1%. The S&P Index has gained 9.5% in the same period.
Image Source: Zacks Investment Research
Factors to Consider Before COR’s Q3 ResultsCencora appears well positioned to deliver another quarter of healthy earnings growth when it reports its results soon. Revenue momentum is likely to have remained constrained by industry-specific pricing dynamics and customer mix changes. Management reiterated confidence in its long-term pharmaceutical-centric strategy, highlighting continued strength in specialty pharmaceuticals, digital transformation initiatives and improving contributions from recently acquired physician management service organizations (MSOs).
Operating performance is expected to have been supported by resilient demand for specialty drugs, expanding oncology services through OneOncology and Regional Cancer Care Associates (RCA), and ongoing productivity initiatives, even as revenue growth faces pressure from manufacturer price reductions, branded-to-biosimilar conversions and moderating GLP-1 sales growth.
Within the U.S. Healthcare Solutions segment, specialty pharmaceutical distribution is likely to have remained the primary growth driver. Continued volume growth from health systems and physician practices, together with increasing contributions from OneOncology, should have boosted operating income. However, revenue growth is likely to have been tempered by manufacturer list-price reductions, lower-margin branded drug conversions at a large mail-order pharmacy customer and slower GLP-1 growth.
The International Healthcare Solutions segment is expected to have maintained healthy momentum, supported by strong European pharmaceutical distribution and the ongoing turnaround in the global specialty logistics business. Contract wins in cell and gene therapies, laboratory logistics and productivity improvements should have continued to boost segment performance. Meanwhile, World Courier’s improving profitability and volume trends are likely to have remained positive contributors.
COR’s operating margins are likely to have continued their expansion, although modest, aided by the higher-margin MSO business, portfolio optimization initiatives and disciplined expense management. Higher interest expense from the OneOncology acquisition and industry pricing changes may have presented modest headwinds. Cencora’s focus on specialty pharmaceuticals, oncology expansion and capital deployment — including resumed share repurchases — should have supported another quarter of solid earnings growth and reinforced confidence in its long-term operating income outlook.
Earnings Beat LikelyOur proven model predicts an earnings beat for COR this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (earnings of $4.43 per share) and the Zacks Consensus Estimate, is +1.37%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Key picksHere are some other stocks from the broader medical space, which you may also consider for your portfolio, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #3 at present. The company is scheduled to release second-quarter 2026 results on Aug. 10.
ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.
BankChampaign National Association acquired a new stake in Cencora, Inc. (NYSE:COR – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,060 shares of the company’s stock, valued at approximately $647,000.
Several other hedge funds have also recently added to or reduced their stakes in the company. Assetmark Inc. grew its holdings in Cencora by 57.0% in the 4th quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after acquiring an additional 24,431 shares during the last quarter. ExodusPoint Capital Management LP purchased a new position in shares of Cencora during the 4th quarter worth approximately $16,487,000. Impact Partnership Wealth LLC bought a new position in Cencora in the first quarter worth $1,170,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Cencora by 162.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock worth $97,735,000 after acquiring an additional 179,086 shares in the last quarter. Finally, SEB Asset Management AB bought a new position in shares of Cencora during the first quarter valued at approximately $134,139,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on COR. UBS Group lifted their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wells Fargo & Company lowered their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Citigroup dropped their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Bank of America boosted their price target on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Finally, Evercore set a $360.00 price target on shares of Cencora in a research report on Wednesday, April 8th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $367.75.
Get Our Latest Research Report on COR
Cencora Stock Down 1.9% COR opened at $312.58 on Friday. The firm has a 50-day simple moving average of $288.61 and a two-hundred day simple moving average of $315.62. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a market capitalization of $60.82 billion, a PE ratio of 23.97, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the business earned $4.42 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.
Cencora Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.
Cencora announced that its board has initiated a share buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
Insider Transactions at Cencora In other news, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.38% of the stock is currently owned by insiders.
About Cencora (Free Report)
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Recommended Stories Five stocks we like better than Cencora Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Has $14.43 Million Stock Position in Artisan Partners Asset Management Inc. $APAM
NEXT HEADLINE »Seagate Technology Holdings PLC (NASDAQ:STX) Given Average Recommendation of “Moderate Buy” by Analysts
Wall Street expects a year-over-year increase in earnings on higher revenues when Cencora (COR - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis prescription drug distributor is expected to post quarterly earnings of $4.37 per share in its upcoming report, which represents a year-over-year change of +9.3%.
Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.27% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Cencora?For Cencora, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.49%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Cencora will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Cencora would post earnings of $4.8 per share when it actually produced earnings of $4.75, delivering a surprise of -1.04%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Cencora appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Cencora letos klesla o 9,7 %, ale těží ze síly amerického zdravotnictví, expanze ve specialitách a nových produktů. Firma zároveň snižuje výhled tržeb kvůli cenovým tlakům a slabšímu růstu GLP-1.
Key Takeaways Cencora is positioned for growth on U.S. healthcare strength, specialty expansion and product launches.COR is integrating OneOncology and RCA to build a scalable specialty care ecosystem across key therapies.Cencora faces pricing headwinds, higher interest expense and regulatory risks despite logistics gains. Cencora (COR - Free Report) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #2 (Buy) company’s shares have lost 9.7% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 Index has gained 7.4% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $58.48 billion.
COR’s bottom line is anticipated to improve 10.1% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 1.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive Factors Driving COR’s ProspectsSpecialty Expansion and MSO Strategy Support Long-Term Growth: Cencora continues to strengthen its position in specialty pharmaceuticals, a market expected to account for more than half of U.S. drug spending in the coming years. During the second-quarter earnings call, management highlighted progress in integrating OneOncology, acquired in February 2026, with Retina Consultants of America (RCA). Management is leveraging both platforms by sharing capabilities in clinical research, trial support and back-office services, creating a scalable specialty care ecosystem. These investments complement Cencora's broader strategy of deepening manufacturer partnerships while expanding services to community providers, positioning the company to benefit from growing demand for oncology, retina and other specialty therapies.
Pharmaceutical Supply Chain Leadership and Expanding Market Opportunity: Cencora's pharmaceutical-centric strategy remains a competitive advantage. The company continues investing in automated fulfillment centers, digital infrastructure and AI-supported tools that improve inventory management, customer visibility and operational efficiency across the pharmaceutical supply chain. These capabilities reinforce Cencora's role as a critical partner for manufacturers and healthcare providers while supporting long-term customer relationships.
The long-term demand backdrop also remains favorable. Industry forecasts project U.S. pharmaceutical spending to grow at an 8.2% CAGR through 2028, supported by rising prescription volumes, specialty therapies and broader patient access. Cencora is well positioned to benefit from sustained GLP-1 utilization, which contributed nearly $1.9 billion of year-over-year sales growth during the quarter despite moderating growth expectations.
International Business and Specialty Logistics Continue to Improve: Cencora's International Healthcare Solutions segment remained another bright spot. International revenues increased 13% year over year, while operating income rose 13.7%, driven by strong European distribution performance and a second consecutive quarter of operating income growth in global specialty logistics. Management highlighted new contract wins in cell and gene therapies, laboratory logistics and continued momentum at World Courier, reflecting improving execution in complex pharmaceutical logistics.
Key Challenges for COR StockRevenue Mix and Pricing Headwinds Could Pressure Reported Growth: Although prescription demand remains healthy, several factors continue to weigh on reported revenue growth. During the second quarter, manufacturer list price reductions created a roughly $2 billion revenue headwind, while faster-than-expected brand conversions at a large mail-order customer and slower GLP-1 growth prompted management to lower full-year revenue guidance. While these factors have a limited effect on operating income because they primarily involve lower-margin products, they can create volatility in reported sales growth and investor sentiment.
Higher Debt and Ongoing Regulatory Risks Remain Watch Points: The OneOncology acquisition has strengthened Cencora's specialty platform but also increased leverage. Net interest expense rose following the acquisition, and management expects approximately $485 million of interest expense in fiscal 2026 despite continued debt repayment efforts.
Beyond leverage, Cencora operates in a highly regulated pharmaceutical distribution environment. Ongoing opioid-related litigation exposure, controlled-substance monitoring requirements and evolving healthcare reimbursement policies could increase compliance costs or create operational challenges, even as the company continues investing in supply-chain integrity and regulatory compliance.
Estimate TrendCOR has been witnessing a stable estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at $17.79 per share.
The consensus mark for third-quarter fiscal 2026 revenues is pegged at $84.89 billion, indicating a 5.2% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.37, implying year-over-year growth of 9.2%.
Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 29.2% against the industry’s 1.6% decline in the year-to-date period.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Cardinal Health’s shares have risen 9.9% against the industry’s 1.6% decline in the year-to-date period.
McKesson has a long-term estimated growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.1%.
McKesson’s shares have edged up 0.5% against the industry’s 1.6% decline in the year-to-date period.
